JP2007503420A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007503420A5 JP2007503420A5 JP2006524408A JP2006524408A JP2007503420A5 JP 2007503420 A5 JP2007503420 A5 JP 2007503420A5 JP 2006524408 A JP2006524408 A JP 2006524408A JP 2006524408 A JP2006524408 A JP 2006524408A JP 2007503420 A5 JP2007503420 A5 JP 2007503420A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydroxy
- compound
- formula
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 47
- 150000001875 compounds Chemical class 0.000 claims 17
- 239000000651 prodrug Substances 0.000 claims 16
- 229940002612 prodrug Drugs 0.000 claims 16
- -1 nitro, cyano, hydroxy, fluoromethyl Chemical group 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 238000001727 in vivo Methods 0.000 claims 8
- 241001465754 Metazoa Species 0.000 claims 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 241000282412 Homo Species 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010051161 Hyperglucagonaemia Diseases 0.000 claims 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 230000035880 hyperglucagonemia Effects 0.000 claims 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 2
- 201000008980 hyperinsulinism Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0319759.7A GB0319759D0 (en) | 2003-08-22 | 2003-08-22 | Chemical compounds |
| PCT/GB2004/003546 WO2005018637A1 (en) | 2003-08-22 | 2004-08-18 | Heterocyclic amide derivatives which possess glycogen phosphorylase inhibitory activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007503420A JP2007503420A (ja) | 2007-02-22 |
| JP2007503420A5 true JP2007503420A5 (https=) | 2007-09-20 |
Family
ID=28460130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006524408A Withdrawn JP2007503420A (ja) | 2003-08-22 | 2004-08-18 | グリコーゲンホスホリラーゼ阻害活性を保有する複素環式アミド誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060264494A1 (https=) |
| EP (1) | EP1656136A1 (https=) |
| JP (1) | JP2007503420A (https=) |
| AR (1) | AR045479A1 (https=) |
| GB (1) | GB0319759D0 (https=) |
| TW (1) | TW200524590A (https=) |
| UY (1) | UY28486A1 (https=) |
| WO (1) | WO2005018637A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0222909D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| GB0222912D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| US20070203111A1 (en) | 2006-01-06 | 2007-08-30 | Sepracor Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
| NZ569608A (en) | 2006-01-06 | 2011-09-30 | Sepracor Inc | Tetralone-based monoamine reuptake inhibitors |
| CN101421228B (zh) | 2006-03-31 | 2014-05-21 | 塞普拉柯公司 | 手性酰胺和胺的制备 |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| CA2688493C (en) | 2007-05-31 | 2016-04-19 | Sepracor Inc. | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
| WO2009158668A1 (en) * | 2008-06-26 | 2009-12-30 | Prolynx Llc | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3706810A (en) * | 1970-09-15 | 1972-12-19 | American Cyanamid Co | N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides |
| US4692522A (en) * | 1985-04-01 | 1987-09-08 | Merck & Co., Inc. | Benzofused lactams useful as cholecystokinin antagonists |
| US4599198A (en) * | 1985-08-02 | 1986-07-08 | Pfizer Inc. | Intermediates in polypeptide synthesis |
| US4720503A (en) * | 1985-08-02 | 1988-01-19 | Merck & Co., Inc. | N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors |
| US4668769A (en) * | 1985-08-02 | 1987-05-26 | Hoover Dennis J | Oxa- and azahomocyclostatine polypeptides |
| FR2601368B1 (fr) * | 1986-07-08 | 1989-04-07 | Synthelabo | Derives de nitrofuranne, leur preparation et leur application en therapeutique. |
| DE3629545A1 (de) * | 1986-08-30 | 1988-03-10 | Bayer Ag | Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| US4751231A (en) * | 1987-09-16 | 1988-06-14 | Merck & Co., Inc. | Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents |
| US5863903A (en) * | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
| US5998463A (en) * | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
| EP1136071A3 (en) * | 2000-03-22 | 2003-03-26 | Pfizer Products Inc. | Use of glycogen phosphorylase inhibitors |
| GB0021831D0 (en) * | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| GB0205170D0 (en) * | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
-
2003
- 2003-08-22 GB GBGB0319759.7A patent/GB0319759D0/en not_active Ceased
-
2004
- 2004-08-18 EP EP04768106A patent/EP1656136A1/en not_active Withdrawn
- 2004-08-18 US US10/567,801 patent/US20060264494A1/en not_active Abandoned
- 2004-08-18 JP JP2006524408A patent/JP2007503420A/ja not_active Withdrawn
- 2004-08-18 WO PCT/GB2004/003546 patent/WO2005018637A1/en not_active Ceased
- 2004-08-20 TW TW093125218A patent/TW200524590A/zh unknown
- 2004-08-20 UY UY28486A patent/UY28486A1/es not_active Application Discontinuation
- 2004-08-23 AR ARP040103023A patent/AR045479A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007503420A5 (https=) | ||
| RU2360912C2 (ru) | Замещенные дигидрохиназолины с противовирусными свойствами | |
| RU2470016C2 (ru) | Производное бипиразола | |
| JP2007501779A5 (https=) | ||
| WO2009063202A3 (en) | Use of crth2 antagonist compounds | |
| WO2008040548A3 (en) | Treatment for non-alcoholic-steatohepatitis | |
| JP2012523395A5 (https=) | ||
| JP2010522710A5 (https=) | ||
| JP2006509749A5 (https=) | ||
| CA2529464A1 (en) | Propionamide derivatives useful as androgen receptor modulators | |
| JP2008534453A5 (https=) | ||
| RU2010102990A (ru) | Производные оксадиазолов в качестве ингибиторов dgat | |
| JP2006507220A5 (https=) | ||
| RU2673622C2 (ru) | Соединения альфа-аминоамидных производных и содержащие их фармацевтические композиции | |
| JP2014505107A5 (https=) | ||
| CN107105660A (zh) | 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法 | |
| JP2007507494A5 (https=) | ||
| RU2011145054A (ru) | Кристаллические формы саксаглиптина | |
| JP5669729B2 (ja) | 代謝性障害を治療するのに有用なサリチレートコンジュゲート | |
| JP2007503421A5 (https=) | ||
| ATE539743T1 (de) | Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan | |
| JP2007500222A5 (https=) | ||
| RU2002101622A (ru) | Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом | |
| WO2010004221A3 (fr) | Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson | |
| JP2008530242A5 (https=) |